Loading...
•
Sep 30, 2025
Jaguar Health Q3 2025 Earnings Report
Jaguar Health reported a slight year-over-year revenue decline with narrowed net losses in Q3 2025.
Key Takeaways
Jaguar Health's Q3 2025 results showed stable revenue compared to the prior year and slightly reduced net loss. Modest gains in prescription product sales were noted, while R&D and administrative expenses saw small changes. A potential new treatment for MVID is progressing with FDA engagement.
Forward Guidance
Jaguar Health is advancing its drug pipeline, particularly crofelemer for MVID, and received FDA guidance for an expedited approval process.
Positive Outlook
- Initial results from MVID trial show promise in extending infant lives.
- FDA meeting held for potential expedited approval path for crofelemer.
- Stable quarterly revenue compared to Q3 2024.
- Slight decrease in operational loss YoY.
- Reduced net loss versus prior year.
Challenges Ahead
- Overall net loss remains high at $9.5 million.
- Interest income turned to interest expense YoY.
- No improvement in Neonorm product sales.
- Mytesi prescription volume fell YoY.
- General and administrative expenses increased due to legal and compliance costs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...